Tryp Therapeutics Provides Update on Clinical Hold for Phase 2a Study for Eating Disorders
SAN DIEGO, Nov. 18, 2021 /PRNewswire/ — Tryp Therapeutics (CSE:TRYP; OTCQB:TRYPF) (“Tryp” or the “Company”), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, announced today that it has received correspondence from the U.S….
Comments Off on Tryp Therapeutics Provides Update on Clinical Hold for Phase 2a Study for Eating Disorders